Corcept Therapeutics(CORT-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low80.12
Day High87.47
Open:81.89
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
StockStory
3 Unpopular Stocks We Steer Clear Of
ASYS
Tipranks
Corcept Resubmits FDA Application for Relacorilant in Cushing’s
Zacks Investment Research
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
Zacks Investment Research
CORT Stock Rises 42% in a Month: Here's What You Should Know
CORT Stock Rises 42% in a Month: Here's What You Should Know
Motley Fool
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
Motley Fool
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?
Tipranks
Corcept Faces Amended Qui Tam Complaint After DOJ Exit
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
H.C. Wainwright Keeps Their Buy Rating on Corcept Therapeutics (CORT)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY), Corcept Therapeutics (CORT) and Taysha Gene Therapies (TSHA)
StockStory
1 of Wall Street’s Favorite Stocks with Exciting Potential and 2 We Question
CENT
Tipranks
Corcept stockholders approve expanded incentive plan and board
Zacks Investment Research
CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up
CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up
StockStory
3 Reasons to Sell CORT and 1 Stock to Buy Instead
CORT
StockStory
3 High-Flying Stocks We Think Twice About
HIMX
Tipranks
Corcept Therapeutics Signals Big Growth After Key Wins
Tipranks
Canaccord Genuity Remains a Buy on Corcept Therapeutics (CORT)
Motley Fool
Corcept (CORT) Q1 2026 Earnings Transcript
StockStory
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures
CORT

Profile

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone), is approved for the once-daily oral treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, suffering from type II diabetes or glucose intolerance and who have failed surgery or are not suitable for surgery.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.